Ligand Pharmaceuticals Incorporated reported earnings of $ 2.67 per LGND share on Oct 29, 2026, beating analysts' expectations by
| Report Date | Oct 29, 2026 |
|---|---|
| Forecasted EPS | $ 2.33 |
| Earnings Per Share (Surprise) | $ 2.67 (+$ 0.34) |
| Last Year's EPS | $ 2.01 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, Ligand Pharmaceuticals Incorporated beat analysts’ expectations 63 times and fell short of expectations 35 time(s). Ligand Pharmaceuticals Incorporated reported earnings per share of $ 2.67 in the last report surpassing an estimated EPS of $ 2.33 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Oct 29, 2026 | $ 2.33 | $ 2.67 | $ 3.09 | |
| Aug 6, 2026 | $ 2.01 | $ 2.37 | $ 1.60 | |
| May 14, 2026 | $ 1.84 | $ 1.63 | $ 1.33 | |
| Feb 26, 2026 | $ 1.46 | $ 2.02 | -$ 1.64 | |
| Nov 6, 2025 | $ 1.97 | $ 3.09 | -$ 0.39 | |
| Aug 7, 2025 | $ 1.42 | $ 1.60 | $ 1.40 | |
| May 8, 2025 | $ 1.21 | $ 1.33 | $ 1.20 | |
| Feb 27, 2025 | $ 1.37 | -$ 1.64 | $ 1.05 | |
| Nov 7, 2024 | $ 1.35 | -$ 0.39 | $ 1.02 | |
| Aug 6, 2024 | $ 1.06 | $ 1.40 | $ 1.42 | |
| May 7, 2024 | $ 0.78 | $ 1.20 | $ 2.28 | |
| Feb 27, 2024 | $ 0.661 | $ 1.05 | $ 1.36 | |
| Nov 8, 2023 | $ 0.61 | $ 1.02 | $ 0.41 | |
| Aug 8, 2023 | $ 0.64 | $ 1.42 | $ 0.34 | |
| May 4, 2023 | $ 0.89 | $ 2.28 | $ 0.58 | |
| Feb 22, 2023 | $ 1.19 | $ 1.36 | $ 1.80 | |
| Nov 7, 2022 | $ 0.45 | $ 0.41 | $ 1.58 | |
| Aug 8, 2022 | $ 0.43 | $ 0.34 | $ 1.63 | |
| May 4, 2022 | $ 0.66 | $ 0.58 | $ 1.41 | |
| Feb 17, 2022 | $ 0.97 | $ 1.80 | $ 1.62 |
Ligand Pharmaceuticals Incorporated’s stock was trading at $ 318.78 on Oct 28, 2026 a day before the last earnings report was released.Following the release of the earnings report, LGND’s price increased to $ 322.75 on Oct 30, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Oct 29, 2026 | $ 2.67 | $ 318.78 | $ 322.75 | |
| Aug 6, 2026 | $ 2.37 | $ 302.57 | $ 293.15 | |
| May 14, 2026 | $ 1.63 | $ 221.21 | $ 213.21 | |
| Feb 26, 2026 | $ 2.02 | $ 191.39 | $ 198.31 | |
| Nov 6, 2025 | $ 3.09 | $ 190.38 | $ 202.48 | |
| Aug 7, 2025 | $ 1.60 | $ 142.40 | $ 150.06 | |
| May 8, 2025 | $ 1.33 | $ 105.62 | $ 104.48 | |
| Feb 27, 2025 | -$ 1.64 | $ 115.01 | $ 122.23 | |
| Nov 7, 2024 | -$ 0.39 | $ 116.90 | $ 121.25 | |
| Aug 6, 2024 | $ 1.40 | $ 98.13 | $ 93.32 | |
| May 7, 2024 | $ 1.20 | $ 72.83 | $ 80.36 | |
| Feb 27, 2024 | $ 1.05 | $ 74.42 | $ 84.35 | |
| Nov 8, 2023 | $ 1.02 | $ 53.16 | $ 54.64 | |
| Aug 8, 2023 | $ 1.42 | $ 66.30 | $ 70.72 | |
| May 4, 2023 | $ 2.28 | $ 75.43 | $ 79.33 | |
| Feb 22, 2023 | $ 1.36 | $ 70.88 | $ 75.09 | |
| Nov 7, 2022 | $ 0.41 | $ 62.00 | $ 69.95 | |
| Aug 8, 2022 | $ 0.34 | $ 60.59 | $ 64.06 | |
| May 4, 2022 | $ 0.58 | $ 58.27 | $ 56.57 | |
| Feb 17, 2022 | $ 1.80 | $ 76.44 | $ 63.98 |
Ligand Pharmaceuticals Incorporated released its most recent earnings reports in October 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Ligand Pharmaceuticals Incorporated beat analysts’ expectations during the last earnings period by
